Last reviewed · How we verify
Androderm®
Androderm delivers testosterone transdermally to replace deficient testosterone in hypogonadal men.
Androderm delivers testosterone transdermally to replace deficient testosterone in hypogonadal men. Used for Testosterone replacement therapy in adult males with primary or secondary hypogonadism.
At a glance
| Generic name | Androderm® |
|---|---|
| Sponsor | Allergan |
| Drug class | Testosterone replacement therapy (TRT) |
| Target | Androgen receptor |
| Modality | Small molecule |
| Therapeutic area | Endocrinology |
| Phase | FDA-approved |
Mechanism of action
Androderm is a transdermal patch that provides continuous testosterone replacement therapy by delivering testosterone through the skin into systemic circulation. It is used to treat testosterone deficiency (hypogonadism) in adult males, restoring normal testosterone levels and associated physiological functions including sexual function, muscle mass, bone density, and mood.
Approved indications
- Testosterone replacement therapy in adult males with primary or secondary hypogonadism
Common side effects
- Skin irritation at application site
- Acne
- Polycythemia (elevated red blood cell count)
- Gynecomastia (breast tissue enlargement)
- Headache
- Mood changes
Key clinical trials
- 52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism (PHASE3)
- Testosterone Supplementation in Patients in Best Supportive Care: Impact on Quality of Life (EARLY_PHASE1)
- Gender-Affirming Hormone Therapy and Its Impact on Myocardial Mass and Cardiac Function, Heart, Liver and Pancreatic Fat Content
- A Phase 4 Study to Evaluate Adrenal Function in Hypogonadal Men Treated With JATENZO® for 12 Months (PHASE4)
- TOTEM RRMS : TestOsterone TreatmEnt on Neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis (PHASE2)
- Testosterone Treatment in Men with Chronic Kidney Disease (PHASE2)
- Evaluation of the Effectiveness of Hormonal Treatment in Adolescents Suffering from Gender Dysphoria (PHASE3)
- Testosterone in Bariatric Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |